Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...196197198199200201202203204205206...10661067»
  • ||||||||||  Kineret (anakinra) / SOBI
    Preclinical, Journal:  Anakinra and dexamethasone treatment of idarubicin-induced mucositis and diarrhoea in rats. (Pubmed Central) -  Mar 7, 2023   
    Dexamethasone reduced apoptosis in the jejunal crypts, both alone and in combination with anakinra. These positive effects encourage further investigations into the use of anakinra and dexamethasone as supportive therapies for chemotherapy-induced intestinal mucositis and diarrhoea.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Clinical, Journal:  Glucocorticoids Accelerate Erythropoiesis in Healthy Humans - Should the Use in Sports Be Reevaluated? (Pubmed Central) -  Mar 7, 2023   
    Intramuscular injection of 40 mg triamcinolone acetonide accelerates erythropoiesis and increase hemoglobin mass but does not improve aerobic exercise performance in the present study. The results are important for sport physicians administering glucocorticoids and prompt a reconsideration of glucocorticoid usage in sport.
  • ||||||||||  ketorolac / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement (clinicaltrials.gov) -  Mar 7, 2023   
    P2,  N=1, Terminated, 
    Trial completion date: Jan 2023 --> Jan 2024 N=40 --> 1 | Trial completion date: Jun 2022 --> Nov 2022 | Recruiting --> Terminated | Trial primary completion date: May 2022 --> Nov 2022; Inadequate patient enrollment
  • ||||||||||  lenalidomide / Generic mfg., Imbruvica (ibrutinib) / AbbVie, J&J
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant (clinicaltrials.gov) -  Mar 7, 2023   
    P1/2,  N=18, Terminated, 
    N=40 --> 1 | Trial completion date: Jun 2022 --> Nov 2022 | Recruiting --> Terminated | Trial primary completion date: May 2022 --> Nov 2022; Inadequate patient enrollment N=63 --> 18 | Trial completion date: Feb 2023 --> Oct 2022 | Suspended --> Terminated | Trial primary completion date: Feb 2023 --> Oct 2022; Per CS0139535 -submitter stated we can update status to Admin complete- low accrual reasoning
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Shockwave: Shock Wave Versus Iontophoresis in Treatment of Subjects With Knee Osteoarthritis (clinicaltrials.gov) -  Mar 7, 2023   
    P=N/A,  N=60, Completed, 
    N=63 --> 18 | Trial completion date: Feb 2023 --> Oct 2022 | Suspended --> Terminated | Trial primary completion date: Feb 2023 --> Oct 2022; Per CS0139535 -submitter stated we can update status to Admin complete- low accrual reasoning Not yet recruiting --> Completed | N=20 --> 60 | Trial completion date: Jun 2021 --> Jan 2023 | Trial primary completion date: May 2021 --> Nov 2022
  • ||||||||||  fentanyl citrate / Generic mfg., dexamethasone / Generic mfg.
    Journal:  Analgesic effect of erector spinae plane block after cesarean section: A randomized controlled trial. (Pubmed Central) -  Mar 7, 2023   
    Ultrasound-guided bilateral ESP provided adequate postoperative analgesia and significantly decreased postoperative fentanyl consumption in patients having cesarean section. Also, it has a longer analgesia time than the control group, and it has been shown to delay the first analgesic requirement.
  • ||||||||||  Xeljanz (tofacitinib) / Pfizer
    Journal:  3D printed multi-drug-loaded suppositories for acute severe ulcerative colitis. (Pubmed Central) -  Mar 7, 2023   
    The suppositories displayed similar dissolution and disintegration behaviours irrespective of their drug content, demonstrating the flexibility of the technology. Overall, this study demonstrates the feasibility of using SSE 3D printing to create multi-drug suppositories for the treatment of ASUC, with the possibility of titrating the drug doses based on the disease progression.
  • ||||||||||  budesonide / Generic mfg.
    Preclinical, Journal:  Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice. (Pubmed Central) -  Mar 7, 2023   
    These data suggest a new and reliable approach for improving the efficacy of budesonide. Our in vivo preclinical data demonstrate the safety and increased efficacy of the budsome platform for IBD treatment, further supporting clinical evaluation of this orally efficacious budesonide therapeutic.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Encapsulation and release of hydrocortisone from proliposomes govern vaginal delivery. (Pubmed Central) -  Mar 6, 2023   
    However, under non-sink conditions, the drug release plateaued at levels corresponding to the encapsulation efficiency. After redispersion, all liposomal formulations performed better than the commercial drug product indicating that the encapsulation into the lipid phase is the main driver sustaining the release.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Trial completion date, Trial primary completion date:  Analgesic Effect of Peripheral Cutaneous Nerve Block of Knee Joint After Total Knee Arthroplasty (clinicaltrials.gov) -  Mar 6, 2023   
    P=N/A,  N=120, Recruiting, 
    Moreover, increase in gestation age was the only factor found to be protective against preterm neonatal mortality. Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jul 2023
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, relacorilant (CORT125134) / Corcept Therap
    Trial completion date, Trial primary completion date, Metastases:  Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer (clinicaltrials.gov) -  Mar 6, 2023   
    P1,  N=24, Recruiting, 
    Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Dec 2023 Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Jan 2023 --> Jan 2026
  • ||||||||||  prednisone delayed-release tablet / Generic mfg.
    Journal:  Evaluaci (Pubmed Central) -  Mar 4, 2023   
    However, there was a significant improvement in CSFT meantime best-correct visual acuity remained stable or improved in 50% of patients. Although none of the measures applied through the FMEA made the failure mode impossible, they made it more detectable and less frequent and reduced the RPN for each failure mode; however, a periodic update of the process is necessary.
  • ||||||||||  mometasone furoate / Generic mfg.
    Session IV Rheum-Derm Grand Rounds: Linter cutaneous lupus erythematosus-an important differential forblaschkoid dermatoses (Ito Hall, University of Tokyo) -  Mar 4, 2023 - Abstract #ISID2023ISID_1828;    
    The patient was managed as LCLE withAPAS, advised sun protection and started on mometasone furoate 0.1% cream twice daily,with noted complete resolution of the linear eruption after 3 months of treatment.To our knowledge, this is the first reported case of linear cutaneous lupus erythematosusin the Philippines...We propose that LCLE be regardedas a primary differential in adult patients presenting with unilateral Blaschkoiddermatoses. Topical corticosteroids may be sufficient in the treatment of LCLE.